OCSL - NASDAQ

Welcome and thank you for joining Oaktree Specialty Lending Corporation’s Second Fiscal Quarter 2025 Conference Call. Today’s conference call is being recorded. [Operator Instructions] Before we begin, I want to remind you that the comments on today’s call include forward-looking statements reflecting our current views with respect to our future operating results and financial performance. Actual results could differ materially from those implied or expressed in the forward-looking statements. Please refer to our SEC filing for a discussion of these factors in further detail. Oaktree no duty to update or revise any forward-looking statements. I’d also like to remind you that nothing on today’s call constitutes an offer to sell or a solicitation of an offer to purchase any interest in any Oaktree fund. Investors and others should note that OCSL uses the investor section of its corporate website to announce material information. The company encourages investors, the media, and others to review the information that it shares on its website. Now I would like to introduce Clark Koury, OCSL Head of Investors, who will host today’s conference call. Mr. Koury, you may begin.

Thank you, operator. Our second quarter earnings release, which we issued this morning along with the accompanying slide presentation, can be accessed on the Investors section of our website at oaktreespecialtylending.com. Joining us on the call today are Armen Panossian, Chief Executive Officer and Chief Investment Officer; Matt Pendo, President; and Chris McKown, Chief Financial Officer and Treasurer. I will now turn the call over to Matt to provide an overview of our performance during the quarter and a couple of updates with regard to our capital structure. Matt?

Thanks, Clark. And thank you to everyone for joining today. Adjusted net investment income was $39 million or $0.45 per share compared to $45 million or $0.54 per share in the first quarter. Our net asset value was $16.75 per share versus $17.63 in the prior quarter. These results reflect ongoing challenges with a few portfolio company investments which we have been and continue to work towards restructuring or exiting. We moved several of these investments to nonaccrual and took additional write downs. As a result, investments on non-accrual status increased to 4.6% and 7.6% of fair market value and cost respectively. This compares to 3.9% and 5.1% in the first quarter. On the positive side, we made progress in resolving several investments on non-accrual including exiting our loan position in SVP-Singer, where we received proceeds totaling $5.7 million, which was consistent with our mark as of December 31. We’ve also seen some increased sales activity in Avery, a luxury mixed use building in San Francisco. Sales picked up in the second half of calendar year 2024 and the trend has continued thus far into 2025. Proceeds from sales go to repaying our loan, enabling us to redeploy capital into new income generating investments. During the last quarter we received proceeds totaling 10% of our cost basis and we expect to receive additional repayments next quarter. In addition, in April we received nearly $100 million from repayments on debt investments, all of which were realized as small premiums as compared to our March 31 valuations. Now, turning to our dividend. In line with our new dividend policy we announced last quarter, our board approved a base dividend of $0.40 per share and a variable supplemental dividend of $0.02 per share for the second quarter. With regard to our balance sheet, we successfully issued new unsecured bonds that mature in 2030 to refinance our existing bonds that matured in February 2025. Additionally, shortly after quarter-end, we successfully amended our senior secured revolving credit facility, extending its maturity and reducing the interest rate from SOFR plus 2% to a range of SOFR plus 1.75% to 1.875%. We appreciate the support of our Bank Group and believe that lower interest expense and associated fees will have a favorable impact on our net investment income. With these positive changes to our capital structure and our leverage at its lowest level in over three years, we have ample dry powder for new investments as we navigate this volatile period. Before I turn it over to Armen, I want to remind you about the meaningful steps we took to more closely align our interests with shareholders. Earlier this year, we amended our incentive fee structure by implementing a total return hurdle and Oaktree purchased $100 million in OCSL shares and a meaningful premium to the share price which provided us with additional capital to deploy into our pipeline. Also, in July of last year, we reduced our management fee to 1% on all assets. We believe these actions demonstrate our commitment to shareholders and to enhancing the long-term earnings power of the portfolio. I’ll now turn it over to Armen to provide more detail on nonaccruals and our investment activities.

Thanks Matt. I’ll start with additions to our non-accruals. Two companies were added to non-accrual status during the quarter. The first was Mosaic Companies, a designer, distributor and retailer of specialty wall and mosaic tile, floor tile and slabs. Mosaic operates three distinct business segments and the sponsor had initiated sale processes for all three. Unfortunately, each of these segments are expected to be impacted by tariffs which affected the sponsor’s efforts to sell. Two of those processes were paused during the quarter. The sale of the third segment closed shortly after quarter end, resulting in a meaningful cash paydown of approximately 50% of our total position. Pro forma for the repayment, we took a conservative approach in valuing the remaining assets, leading to a markdown of approximately 76% on the unsold portions. Despite being placed on non-accrual, the material cash recovery reflects progress in our efforts to manage and resolve the position. We are actively working to sell the remaining two business segments. The second addition was SiO2, a manufacturer of a hybrid material that combines glass and plastic for medical use in diagnostic tubes, vials and syringes. Our prior position in the company was restructured in August of 2023 and this quarter, we placed a restructured loan on non-accrual due to the company’s continued cash needs. We marked down the loan by about 69% at quarter-end. The company recently signed a new contract and is pursuing several other opportunities and license agreements. We remain focused on supporting the company in these strategic initiatives. Although it’s not new to our non-accrual list, Dialyze is another investment where we took a significant markdown. We placed the company’s first lien term loan on non-accrual in the December quarter, given the company’s ongoing cash needs. We continue to be actively engaged with management and other stakeholders to evaluate the best path forward, but unfortunately the situation has not materially improved and this quarter, we marked the loan down by about 76%. While we’re clearly not pleased with how SiO2 and Dialyze have trended, these two positions now represent less than 1% of the portfolio at fair value. Turning now to investment activity for the quarter. We committed $407 million of capital across 32 investments consisting of 24 new borrowers and 8 existing borrowers. This compares to 13 investments totaling $198 million in commitments last quarter. The weighted average yield on our new debt investments was 9.5% versus 9.6% in the prior quarter. Increasing portfolio diversification remains a focus as we took the number of positions to 152, 136 last quarter. We continue to emphasize investments at the top of the capital structure and consistent with the first quarter approximately 84% of the portfolio was invested in senior secured loans, including 81% in first lien loans. To mitigate risk in the current environment, we are prioritizing investments in larger more diversified businesses that have the financial and operational ability to withstand uncertain times. As of March 31, the median EBITDA of our portfolio companies was approximately $158 million, a $16 million increase from the prior quarter. The leverage in our portfolio companies was steady at 5.4 times, well below overall middle market leverage levels. The portfolio’s weighted average interest coverage based on current base rates declined slightly to 1.8 times compared to 2.1 times last quarter. Looking at our second quarter originations, I’d like to highlight two noteworthy loans we made to Vantive and Barracuda. The healthcare sector remains a strong focus for us given its critical need and sustainable outlook. Vantive is a global leader in the development and manufacturing of capital equipment and consumables for both acute and chronic dialysis therapies. As a recognized innovator, Vantive holds the number one position in the non-clinical peritoneal dialysis market, demanding approximately 73% market share. This financing facilitated Carlyle Group’s acquisition of Vantive, structured as a $2.5 billion first lien term loan and a $450 million revolving credit facility. Oaktree provided $425 million of the term loan, which carries a coupon of SOFR plus 5% along with $77 million of the revolving credit facility. OCSL was allocated $61 million of the total deal. We also like service providers with recurring cash flow models and made an investment in Barracuda, provider of cloud enabled email data and network cybersecurity solutions for middle market and small to midsized businesses. This financing sits alongside the company’s syndicated first lien and second lien term loans and proceeds were used to bolster the company’s liquidity position. Oaktree led this transaction and provided $100 million of the total $200 million term loan priced at SOFR plus 6.5% with OCSL receiving $15.5 million. We believe these transactions highlight the strength of Oaktree’s deal sourcing platform and our capacity to participate in larger scale opportunities, advantages we believe set us apart from other market participants. I’ll now turn to an overview of exit and repayment activity during the quarter. Investment exits slowed in the second quarter totaling $279 million, primarily driven by fewer sales within our liquid portfolio. As you may recall from our remarks last quarter, we took advantage of strength in the public credit markets late last year and sold certain investments that we believe were fully valid. Now, I will turn the call over to Chris, discuss our financial results in more detail.

Thank you, Armen. In our second fiscal quarter ending March 31, 2025, we delivered adjusted net investment income of $38.7 million, or $0.45 per share, as compared to $44.7 million or $0.54 per share in the prior quarter. The decrease was primarily driven by lower total investment income, partially offset by reduced interest expense and Part 1 incentive fees during the quarter. Adjusted total investment income in the quarter declined $9.9 million compared to the prior quarter, primarily due to a decrease in interest income resulting from a smaller average investment portfolio, the impact of placing new investments on non-accrual status and declining reference rates. Net expenses declined $3.8 million from the prior quarter, driven by a $2.4 million decrease in interest expense due to lower outstanding borrowings and lower reference rates on our floating rate liabilities and a $1.5 million decrease in Part I incentive fees net of fees waived, reflecting the impact of the total return hurdle. Now, moving to our balance sheet. Our net leverage ratio at quarter end was 0.93 times, down from 1.03 times last quarter. As of March 31, total debt outstanding was $1.47 billion and had a weighted average interest rate of 6.7%, including the effect of our interest rate swap agreements. This is up from last quarter, primarily reflecting the impact of refinancing our 3.5% fixed rate bonds that matured in February with new bonds mature in 2030. In connection with issuing the new bonds, we entered into an interest rate swap agreement translating to a coupon of SOFR plus 2.19%. Unsecured debt represented 65% of total debt at quarter end, up from about 59% last quarter. We have plenty of dry powder to fund investment commitments with liquidity of approximately $1.1 billion. This includes $98 million of cash and $1 billion of undrawn capacity on our credit facilities following the recent amendment that Matt described earlier. Unfunded commitments excluding those related to the joint ventures were $273 million, approximately $252 million of which can be drawn immediately as the remaining $21 million is subject to portfolio companies meeting certain milestones before the funds can be drawn. Our target leverage range remains unchanged at 0.9 times to 1.25 times. We are currently at the low end of that range due to a combination of successful investment exits, Oaktree’s $100 million equity investment in the March quarter and our prudent approach to deploying capital given market volatility. Turning now to our joint ventures. Together, the JVs currently hold $440 million of investments, primarily in broadly syndicated loans spread across 54 portfolio companies. During the second fiscal quarter, the JVs again generated attractive annualized ROEs, which were approximately 10.6% in aggregate. Leverage at the JVs was 1.3 times, up slightly from last quarter. In addition, we received a $700,000 dividend from the Kemper JV. With that, I would like to turn the call back to Armen to provide some color on the market environment.

Thanks, Chris. Before opening the call up to questions, I’ll provide some brief commentary on the market environment. Since the end of the second quarter, we have experienced some of the most volatile public market conditions since the pandemic in March of 2020. There is significant uncertainty surrounding the trade environment, including what new tariffs may arise, potential retaliatory measures from other countries, and how long these policies will remain in place. Despite the wide range of potential outcomes, we believe we can make the following observations with some certainty. Despite an optimistic outlook for a pickup in M&A activity earlier this year, activity has been slow and is likely to remain that way until we have more clarity around the economic outlook. We expect many lenders will be more cautious around capital deployment as they focus on the health of existing portfolio companies. In this environment, companies that were once supported by easy credit and low interest rates are now grappling with tightening liquidity, rising borrowing costs, and disrupted supply chains driven by global trade upheavals. It will be a couple of quarters before tariffs roll through the supply chain and impact portfolio company performance, so it’s too early to assess the real impact now. That said, well in advance of the actual tariff announcements, we were considering their potential impact on existing and prospective investments. This heightened focus factored into our underwriting and risk evaluation, and we are proactively selling investments within our liquid portfolio that we perceive to have more exposure to negative impacts from tariffs. We are also focused on further diversifying our portfolio by selectively investing in companies we believe are well positioned to deliver attractive returns given market uncertainty caused by tariffs as well as inflation and high interest rates. Recently there has also been an uptick in demand for capital solutions or rescue financing, which could benefit managers like Oaktree that have significant experience and expertise in this area. Historically, in periods of market volatility, our firm-wide DNA has enabled us to capitalize on opportunities while others are sidelined and we have the dry powder to do so again if appropriate opportunities arise. In closing, we believe OCSL is well positioned to navigate the current market environment and to deliver attractive risk adjusted returns to our shareholders over the long-term. We appreciate your participation on our call today. And now we will take your questions. Operator, please open the line.

Thank you.

The next question comes from Melissa Wedel with JPMorgan. Please go ahead.

Good morning. Thanks for taking my questions. Really trying to discern sort of run rate NII, given the markdowns on the portfolio and the additions – changes in non-accruals. It seems like with some stabilizing base rates this could be sort of what we could expect in that given no changes in base rates this could be a run rate level NII. Is that fair to say or are you seeing other things happening in the portfolio that could impact that?

Hey Melissa, it’s Chris. Thanks for the question. [Indiscernible] Matt want to chime in, please feel free. I think a couple things we’re focused on. We mentioned in our prepared remarks that we finished the quarter at 0.93 times net leverage. So definitely kind of the low end of our range and where we’ve been operating historically. Our average portfolio throughout the quarter was a little bit lower versus prior quarters. So as Armen mentioned, we’re going to be patient around deployment but over time, we are mindful of in fact lowering our leverage range than where we’ve been operating. And then I think the other focus and I think Matt mentioned it in his comments just around working through some of these situations on non-accruals, turning those into cash producing assets is definitely a continued focus of ours.

And I think, Melissa, it’s Matt. The other area continue to focus on is the JVs and putting more assets in there, running leverage a little bit higher there. They invest mostly in BSL. So those are – it’s relatively more easy to deploy there than in some of the private assets that the sales cycle is a little bit longer. So that’s just the other point I’d make.

Sure. And to that point on leverage and then deploying within the joint ventures. I mean, obviously, this quarter seems very different from even the March quarter. When we look at sort of the repayment levels that you’ve seen in the portfolio and exits – repayments and exits over the last three quarters, they’ve been pretty sizable. Should we be expecting any slowing of repayment activity during this period of volatility? Or would you expect that to remain pretty elevated?

Melissa, this is Armen. I could take a crack at that. So a couple of things. In terms of liquid credit, in the back half of last year, especially the fourth quarter as the markets were pretty tight, we actually were just generally a net seller of liquid credit, and so we actually delevered those JVs as a result of that. I think given the volatility in the last four to six weeks in the public markets and our anticipation of further volatility in those markets given what I would expect would be a challenging tariff backdrop for a while. I would expect that we will find some opportunities to deploy into the joint ventures and increase their leverage again. We’re looking for good deals that are or good companies that are trading discounted, and we don’t think it’s there yet. They traded-off 2, 3, maybe 3.5 points in late March and into April. And they’ve recovered maybe half of that point move. And so – and if you look at high yield bonds, the spreads had widened to 4.35%, 4.40-ish during that timeframe. They’re now back to sort of 3.75%. They are pretty volatile though, quite sort of up and down, but we think that as performance starts to show up in the second calendar quarter this year and into the third, there’s probably going to be volatility in the public credit and equity markets that we think we could take advantage of for the JVs. In the case of private credit, we actually have had some exits since the end of the quarter. And so I think we – those are more idiosyncratic, not really reflective of necessarily a tightening credit story. It was just situations that resolved. So I think our repayments for the quarter are not going to be immaterial. I think they will be up for the quarter ended June. I think they’ll still be significant enough. But again – but yes, I think your instinct is correct that if the markets are volatile that generally speaking, repayments, refinancings should slow down. And I would expect to see that over the coming quarters as well.

Thanks very much.

Thank you. [Operator Instructions] The next question comes from Paul Johnson with KBW. Please go ahead.

Thank you. Thanks for taking my questions. Just on the kind of run rate question of income, just looking at the portfolio yield this quarter, think it was down 50 basis points or so. But if I take a quick average of just kind of the debt portfolio yield quarter-over-quarter, it looks like it’s down a little over 100 basis points. So I’m just curious, is there any kind of one-time stuff that’s flowing through there that would – is this yield, I guess, that we have today reflective of kind of what you think the portfolio should generate going forward?

Yes. Hey, it’s Chris. Appreciate the question. Yes, I think a couple of factors. I think looking at sort of the quarter-on-quarter decline in interest income. Part of that is just due to reference rate declines in the December quarter rate sets for about half the book were based on 930 [ph] base rates. So those reset at the end of December in light of the rate cuts that happened in the fourth calendar quarter that played through in the March quarter. So that’s part of it. And as far as the quarter-on-quarter decline in yield, you’re seeing from the 10.7% reported last quarter to the 10.2% this quarter, majority of that 30 bps worth was due to the impact of the new non-accruals, which we’ve discussed. And a little bit of call it lingering timing with respect to reference rate resets and also some spread compression quarter-on-quarter. So I do think that where we’re at now is a decent run rate on the book.

Okay, thank you for that. And then you partly answered my question here. But on the JV, the 10.6% ROE, is that a net ROE as opposed to like an operating ROE on the JV?

That’s looking at the NII of the JV. I should say, the NII plus the coupon interest on the subordinated note.

Okay. Because that’s pretty close to what you’re generating on the balance sheet. So it sounds like, you may find some opportunities to increase leverage there and put some investments into the JV. So with leverage I guess what do you think you could potentially get the JV to in terms of an ROE over time?

I think it would depend on the opportunity set. I mean certainly getting back up into the call it the 11%, 12% context I think is achievable, but we’ll ultimately depend on the opportunities that we’re seeing there.

Appreciate it. That’s all for me.

Thank you. This concludes the question-and-answer session. I would like to turn the conference back over to Clark Koury for any closing remarks.

Thank you, operator, and thank you all for joining us on today’s call. A replay of the earnings call will be available in approximately one hour, and you can access that on the Investor section of OCSL’s website. Please feel free to reach out to me and team with any questions you may have. Thanks again for your participation and support.